Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma for whom enucleation has been recommended.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces research collaboration with Attmos
- Cautious Hold Rating on IDEAYA Biosciences Amid Anticipated Equity Raises and Financial Pressures
- IDEAYA Biosciences Reports 2024 Financials and Business Update
- IDEAYA Biosciences: Strategic Advancements and Promising Clinical Developments Support Buy Rating
- Strategic Advancements and Clinical Progress Drive IDEAYA Biosciences’ Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue